Opinion
Video
Experts underscore the importance of patient-reported outcomes in tailoring treatments for dry eye disease in patients.
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Haumschild notes the importance of patient-reported outcomes in assessing dry eye disease (DED) treatment effectiveness given the impact on vision and activities of daily living.
Parekh emphasizes regular patient follow-up every 3 to 6 months to ascertain treatment response and adverse reactions, ensure adherence, and modify therapy as needed rather than set return visits yearly. This parallels comprehensive management of glaucoma and cataracts. He notes many new DED options are now available, including anti-inflammatories, treatments targeting evaporative DED, over-the-counter artificial tears, and short-term topical steroids.
Kabiri reflects on how the understanding of DED pathophysiology has evolved. Where DED was previously viewed as either dryness driving inflammation or inflammation driving dryness, most DED is now considered evaporative, with subsequent surface damage enabling inflammation. Newer treatments targeting early evaporative DED may help prevent downstream inflammation. Haumschild concurs that appropriate sequencing of newer evaporative and traditional anti-inflammatory DED treatments offers expanded options for comprehensive management.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.